Harrow, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-09-30 was 0.00 shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-03-31 was 15.00K shares, a 39.29% increase year-over-year.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-12-31 was 119.53K shares, a 6023.21% increase year-over-year.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 130.46K shares, a 42.58% decline from fiscal 2014.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2014 was 227.22K shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2012 was -200.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 134.53K shares derived: sum of 4 quarters · filed 2017-03-21 |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 134.53K shares derived: sum of 4 quarters · filed 2017-03-21 |
| 2016-03-31 | 15.00K shares 10-Q · filed 2016-05-12 | 134.69K shares derived: sum of 4 quarters · filed 2017-03-21 |
| 2015-12-31 | 119.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | 130.46K shares 10-K · filed 2017-03-21 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 12.88K shares derived: sum of 4 quarters · filed 2015-11-12 |
| 2015-06-30 | 163.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | 117.10K shares derived: sum of 4 quarters · filed 2015-08-12 |
| 2015-03-31 | 10.77K shares 10-Q · filed 2015-05-13 | 148.08K shares derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-12-31 | 1.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | 227.22K shares 10-K · filed 2015-03-12 |
| 2014-09-30 | 104.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | |
| 2014-06-30 | 31.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | |
| 2014-03-31 | 89.91K shares 10-Q · filed 2014-05-15 | |
| 2013-03-31 | -1.03K shares 10-Q · filed 2013-05-08 | |
| 2012-12-31 | -200.00 shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |